Initial Product. Within 6 months of the Effective Date of this Agreement, the Development Committee will provide DTI with an Initial Product Development Plan setting forth ▇▇▇▇▇▇▇'▇ anticipated development program for the Initial Product in the Territory, including target dates for key clinical and regulatory events in the Major Countries. Such plan shall specify the dates by which ▇▇▇▇▇▇▇ shall enroll the first patient in a pivotal Phase III study and file for regulatory approval in the first Major Country (these two dates are hereafter referred to as the Critical Target Dates). Such plan shall be finalized by the Development Committee and approved by DTI not later than 7 months after the Effective Date. Exhibit F contains a reasonable preliminary plan which has been reviewed by both parties.
Appears in 3 contracts
Sources: Exclusive License Agreement (Aderis Pharmaceuticals Inc), Exclusive License Agreement (Aderis Pharmaceuticals Inc), Exclusive License Agreement (Aderis Pharmaceuticals Inc)